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The purpose with this study was to compare multi-criteria optimization 
(MCO) for volumetric modulated arc therapy (VMAT) treatment plans in 
two different treatment planning systems.   
Theory: When performing treatment planning prior to radiation therapy it is important 
to prioritize between absorbed dose to target and absorbed dose to organs at 
risk (OAR). A treatment plan where one treatment goal cannot be improved 
without impairing another treatment goal is called a Pareto optimal plan. 
MCO has been proposed as an alternative optimization method for VMAT 
treatment plans, which will provide several solutions of alternative treatment 
plans that is at, or close to the Pareto front. The treatment planning system 
will make it possible for the user to navigate between the possible solutions 
that the optimization has created and choose the plan that best fulfils the 
treatment planning goals.  
 
 
Method: Five patients with prostate cancer and five patients with head and neck 
(H&N) tonsil cancer have been anonymously selected consecutively from the 
clinical database at Sahlgrenska University Hospital. New VMAT treatment 
plans were made with MCO in Eclipse (Varian Medical Systems) and 
RayStation (RaySearch Laboratories). The aim was to give both treatment 
planning systems (TPS) the same conditions in order to compare the plans 
fairly. The MCO created Pareto plans and generated a slider for each 
objective selected. The sliders were thereafter moved to reduce the dose to 
the organs at risk as much as possible, but at the same time maintain the 
target dose coverage. Evaluation of the treatment plans was made by 
evaluating chosen points in the calculated dose-volume histogram but also by 
evaluating conformity index, heterogeneity index and the complexity of the 


















Dosimetrically, treatment plans created in Eclipse MCO usually provided 
lower values to the OARs than the treatment plans created in RayStation 
MCO, but after post processing, RayStation usually provided lower values to 
the OARs than the treatment plans created in Eclipse MCO. The mean value 
of the conformity index for Eclipse MCO and RayStation MCO with post 
processing was 0.9 and 0.78 respectively for the prostate cases and 0.87 and 
0.81 respectively for the H&N cases. The values for the heterogeneity index 
were similar in both TPSs. The calculated complexity index was, in most 
cases, similar for the prostate cases, however the treatment plans for the 
H&N cases created in RayStation had generally a lower value of complexity 
than those created in Eclipse.  
 
 
MCO has proven to be a useful tool for VMAT treatment planning. The 
management procedure differed for the two TPSs, however, it was in most 
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Cancer includes approximately 200 diagnoses which signify uncontrollable cell division. 
There are several treatment methods for cancer, for instance surgery, chemotherapy, 
immunotherapy and radiation therapy. Radiation therapy has been a treatment method since 
the late 19th century and contributes to 30% of all cancer cures. However, radiation therapy 
can be either curative (to cure the disease) or palliative (to relieve an incurable disease) and 
half of all cancer patients will receive radiation therapy some time during their treatment [1]. 
There are several methods to deliver radiation therapy, but this study will focus on photon 
beam therapy generated by linear accelerator.   
 
The treatment planning process prior to radiation therapy forms the basis of the entire 
treatment and defines the intended treatment outcome for the patient. What is most important 
with the treatment planning is to prioritize between absorbed dose to target and absorbed dose 
to organs at risk (OARs). The treatment planning process involves many steps which begins 
with image acquisition, e.g. computed tomography (CT), magnetic resonance imaging (MRI), 
to collect patient-specific data [2]. This follows by anatomy definition where different 
treatment volumes are delineated according to recommendations from ICRU [3,4]. The 
treatment volumes have three different definitions starting with the gross tumor volume 
(GTV) which is the visible tumor shown on for example CT-images. The volume that 
contains GTV and/or subclinical microscopic disease is referred to as the clinical target 
volume (CTV). Finally, the planning target volume (PTV) contains CTV and margins for 
possible geometric variations which includes internal patient motion and patient set up 
variations. Surrounding OARs are also defined and delineated in the images. In some cases, 
an extra margin analogous to the PTV margin around an OAR is needed [4]. This applies to 
so called serial organs, where the maximum dose is important but irradiated volume is less 
important, such as for example the spinal cord. For the spinal cord, damage to a small part of 
the tissue can have a great clinical significance and an extra margin around the organ is 
therefore needed to ensure that there are no regions of high dose close to the organ. For so 
called parallel organs, the mean dose is more important than the maximum dose and the organ 
can maintain its function up to irradiation of a certain critical volume [2]. 
 
After the image acquisition and structure definition the treatment plan is created in a treatment 
planning system (TPS) where calculation of the dose distribution can be made. One of many 
challenges during treatment planning is to generate a treatment plan with a conformal dose 
distribution. A conformal dose distribution means that the shape of the high dose region 
mimics the shape of the target volume, i.e. the tumor and the surrounding OARs shall receive 
a high and low absorbed dose respectively. It is important to create a conformal dose 
distribution since it might result in undesirable complications otherwise. Too low dose to the 
tumor can cause continued tumor growth, while too high dose to the OARs can cause 
damaging of the healthy tissue and in turn lead to negative side effects of the treatment. The 





1.1 Volumetric modulated arc therapy (VMAT) and treatment planning goals 
At present, more than 50% of all curative treatments are treated with volumetric modulated 
arc therapy (VMAT) at Sahlgrenska University Hospital. Treatment plans made with VMAT 
have shown to have a higher conformity and reduced treatment time, compared to previous 
treatment techniques [5]. VMAT modulates the position of multi-leaf collimator (MLC), the 
dose rate and in some cases also gantry speed simultaneously with irradiation and gantry in 
rotation, in one single or multiple arcs.  
 
The treatment plan optimization process for VMAT is called inverse treatment planning 
where the beams are created from the desired dose distribution. The desired dose distribution 
is described by treatment planning goals. Typical parameters to describe dosimetric goals in 
the TPS include minimum and maximum dose to targets and OARs, but also minimum and 
maximum volume of targets and OARs that should or should not receive a given dose, here 
referred to as dose/volume parameters. One example of a dose/volume parameter goal is D98% 
≥ 95% for PTV, which means that the dose given to at least 98% of the PTV volume should 
be equal to 95% of the prescribed dose or more. Another example is V90% < 15% for rectum 
which means that 90% of the prescribed dose should only be delivered to less than 15% of the 
volume of rectum. The goals defined for the optimization that is describing the desired dose 
distribution are called objectives. The equivalent uniform dose (EUD) [6] can be described by 












where N denotes the number of voxels in the structure, 𝐷! 	is the dose in the ith voxel and a is a 
parameter which is related to the dose-volume effect. When a approaches a large negative 
value, the value of EUD approaches the minimum dose and can be applied for tumors. When 
a instead approaches a large positive value, EUD approaches the maximum dose and can be 
applied for serial organs, such as for example the spinal cord. Finally, when a is 1, the value 
of EUD becomes the mean dose and can be applied for parallel organs, such as for example 
rectum.  
 
Not only objectives could be used during the optimization, but some TPS also have the 
possibility of using constraints which are goals that must be fulfilled. Constraints can be used 
for example to describe treatment goals for serial organs. For the TPS not having the 
possibility of adding constraints, objectives with different priorities are used. When the 
definition of objectives/constraints have been done, the treatment plan is created through an 
automated iterative optimization. 
 
1.2 Pareto front 
For one patient who is to achieve radiotherapy there will exist many possibilities for a 
treatment plan. A treatment plan where one treatment goal cannot be improved without 
impairing another treatment goal is called a Pareto optimal plan. The concept of Pareto 
optimality was first introduced by Vilfredo Pareto as a mathematical concept, which is 
describing a problem with contradicting objectives and many solutions. The Pareto optimal 
treatment plans for a specific patient and treatment intent to create a surface called the Pareto 
front [7]. It is indefinite if Pareto optimal plans are being created in the inverse treatment 
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planning procedure for VMAT. This because of limitations in the optimization procedure 
which may imply that different TPS do not have the same opportunity to create Pareto 
optimal treatment plans. 
 
1.3 Multi-criteria-optimization (MCO)  
Even though VMAT has proven high dose conformity, there are still some limitations. The 
treatment plan may, for example, depend on the optimization algorithm in the TPS but also on 
the experience of the planner and the time spent on treatment planning. As a way to reduce 
these problems, multi-criteria-optimization (MCO) has been proposed as an alternative 
optimization method [8-11]. MCO is available in some TPS for example in Eclipse (Varian 
Medical Systems) and RayStation (RaySearch Laboratories) which both will be evaluated in 
this study. The goal of MCO is to create several treatment plans that are as close to the ideal 
Pareto front as possible. The user can then navigate between the possible solutions that the 
optimization has created and choose the plan that best fulfils the treatment planning goals. 
The possible solutions, i.e. the alternative plans, will henceforth be referred as the Pareto 
plans in both Eclipse and RayStation.  
1.3.1 MCO Eclipse 
An initial treatment plan is required before entering the MCO trade-off exploration in Eclipse. 
A copy of the initial treatment plan is called a balanced plan which forms the basis of creation 
of the Pareto-plans. In the MCO optimization the user can choose N objectives from the initial 
treatment plan. The number of Pareto plans created in the MCO is determined according to 
3N + 1 [12]. For each selected objective, a slider will appear. The dose distribution will be 
updated in real time on the screen when the sliders are drawn to the left/right to navigate 
between the Pareto plans to improve/degrade the objectives. The sliders can be moved until 
the user is satisfied. Thereafter the final dose calculation of a deliverable plan is made 
according to the limitations of the treatment machine.  
1.3.2 MCO RayStation 
In RayStation MCO the number of Pareto plans is determined by the user. The minimum 
number of plans is N + 1, were N still represents the optimization objectives. To create Pareto 
plans in RayStation not only objectives are required but also constraints. In RayStation the 
objectives and constraints are listed in the MCO workspace and no initial treatment plan is 
required. When the objectives and constraints have been defined, the Pareto plans can be 
generated and the different sliders for each objective will appear. Note that the constraints 
cannot be changed with slides in the navigation process. When the user is satisfied, the final 
plan will be determined based on a dose calculation including the limitations of the treatment 
machine. RayStation also offers a possibility for post processing of the treatment plans from 
MCO. When using post processing, the optimization functions used in the MCO workspace 
are copied to the general Plan optimization module [13]. The optimization can thereafter be 
continued in the general Plan optimization where new objectives and/or constraints can be 
added. This can be useful in some cases, for example when it is desired to further reduce the 
dose to an OAR.  
 
1.4 Plan quality 
After the treatment plan has been made it is important to evaluate the calculated dose 
distribution. This can be made by calculating a cumulative dose-volume histogram (DVH) 
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which display the dose distribution within a volume of interest in the patient [2]. A DVH is 
illustrated in figure 1 for a prostate patient where treatment planning goals, such as for 
example V90% < 15% for rectum, can be evaluated.  
 
 
Figure 1: Example of a cumulative DVH for PTV, rectum and CTV from a treatment plan for a prostate patient. 
The black line represents how the treatment planning goal V90% < 15% for rectum can be evaluated. From 90% of 
the dose at the x-axis where the black dot is located, the value of the volume is represented by the y-axis. In this 
case V90% is about 14%.  
The DVH is, however, not enough as a sole evaluation tool since it is important to review the 
spatial dose distribution, i.e. the dose distribution in the patient’s 3D volume. This is 
important for localization of any low or high-dose regions, also known as cold- or hotspots.  
 
Other evaluation tools are for example a homogeneity/heterogeneity index which refers to 
uniformity of the dose distribution within a target volume, and the dose conformity index 
which is a measure of how well the high dose volume conforms to the target volume [14]. It is 
also important to keep in mind that the calculated dose distribution may not necessarily be the 
same as the dose distribution that will be delivered to the patient. Large differences between 
the calculated and the delivered dose can be due to a high complexity and that the treatment 
plan is not sufficiently robust to variations during delivery. Even treatment plans with similar 
calculated dose distributions may have different complexity that can affect the difference 
between the calculated and delivered dose differently. The complexity can be estimated with a 





The aims with this study was to evaluate the capability of MCO for VMAT treatment plans 





2.1 Patient data and treatment planning goals  
Planning CTs from five patients with prostate cancer and five patients with head and neck 
(H&N) tonsil cancer had been anonymously selected consecutively from the clinical database 
at Sahlgrenska University Hospital to be included in this study. Patients with obvious 
discrepancies, such as a very large neck or none at all, were exchanged with the subsequent 
patient. The patients had previously been treated with VMAT. The patients were anonymized 
and transferred from the clinical system to a research system. 
 
The prostate cases covered intermediate- and high-risk cancer patients with a prescribed dose 
of 66 Gy in 22 fractions, 3 Gy per fraction. This was according to local clinical guidelines for 
prostate cancer radiotherapy. This study focused on rectum as an OAR. However, the bladder 
and capiti femori are also OARs that are taken into account in the local clinical guidelines. 
The H&N cases had two different target volumes named PTVT and PTVN which were treated 
with two different prescribed doses. The prescribed dose for PTVT was 68 Gy in 34 fractions 
with 2 Gy per fraction. The prescribed dose for PTVN was 52.7 Gy with 1.55 Gy per fraction. 
PTVN consisted of lymph nodes and was treated for preventive purposes. This study focused 
on the OARs listed in table 2, however, the brain stem, pharynx and cochlea are also 
objectives taken into account in the local clinical guidelines that are based on the clinical 
study protocol Artscan III. 1  
The treatment goals for both prostate and H&N cases are summarized in table 1 and 2. Note 
that table 1 and 2 only reports selected OARs for this study. Regarding table 2, the treatment 
goals have been converted from Gray (Gy) in the clinical protocol, to percent (%), and the 
goal values for the objectives are rounded to full percent.  
Table 1: Dose-volume treatment goals for prostate cancer radiation treatments according to local clinical 
guidelines. Note that capiti femori and the bladder are also OARs included in the local clinical guidelines. 
Priority Volume Dose/volume objectives 
1 CTV Dmin ≥ 97% 
2 PTV D98% ≥ 95% 
3 Rectum V90% < 15% 
4 Rectum D2% ≤ 100% 
5 Rectum V50% < 50% 







1 ARTSCAN III. A randomized multicentre phase III study of cisplatin plus radiotherapy compared to cetuximab 




Table 2: Dose-volume treatment goals for H&N treatments. Note that the brain stem, pharynx and cochlea also 
are objectives taken in account in the clinical guidelines and according to the study protocol Artscan III 1.  Also, 
note that larynx to body have the same priority. 
Priority Volume Dose/volume objectives Constraint 
1 PRV spinal cord 
 
D2% ≤ 68% * 
2 PTVT D98% ≥ 95% 
 
3 PTVN D52.7% ≥ 74% 
 
4 Parotid glands Dmean ≤ 37% (both glands) 
Dmean ≤ 29 % (one gland) ** 
 
5 Larynx Dmean ≤ 59% 
 
5 Oral cavity Dmean ≤ 35% 
 
5 Upper esophageal sphincter Dmean ≤ 59% 
 
5 Mandible D2% ≤ 103% 
 
5 Submandibular glands Dmean ≤ 57% 
 
5 Body Dmax ≤ 107% 
 
* The constraint for D2% to the PRV spinal cord is 71% (48 Gy) according to Artscan III 1 but a lower             
value was used as a constraint in this study, since that is used for the local treatments.  
** The mean dose to each parotid gland should aim to be equal to or less than 37% of the prescribed dose. 
If only one gland can be spared, the mean dose should aim to be equal to or less than 29% of the prescribed 
dose to that gland1.  
 
2.2 VMAT treatment plans  
The treatment plans for this study were made in Eclipse version 15.6.04 (Varian Medical 
Systems) using the Analytical Anisotropic Algorithm (AAA) and RayStation version 8B(R) 
(RaySearch Laboratories) using the Collapsed Cone algorithm (CC). All treatment plans in 
this study were made by a beginner in treatment planning under the supervision of an 
experienced planner in Eclipse. Some supervision was also maintained by an application 
specialist from RaySearch in order to better understand the operations in RayStation. The aim 
was to give both TPSs as similar conditions as possible in order to compare the plans more 
fairly. The treatment plans were made using 2 arcs and beam energy of 6 MV photons. The 
dose grid resolution was set to 0.25 cm/voxel and the gantry spacing between control points to 
2 deg. The treatment plans were created for a Varian True beam linear accelerator (Varian 
Medical Systems) with a Milennium multi leave collimator (MLC) which rotated from 179 to 
181 degrees counterclockwise for the first arc and 181 to 179 degrees clockwise for the 
second arc.  
 
According to the definition of ICRU, PTV is a direct expansion of CTV in all directions [3,4].  
The PTVs for the treatment plans in the H&N-region were therefore often located close to, or 
in some cases even outside of, the body surface where it would be physically impossible (and 
not clinically relevant) to achieve the treatment planning goals. This is due to build up effects 
from air to body. In those cases, a structure of water from PTVT and PTVN that extended 
outside of the original body-contour was added to the CT-scans. The structure extended 
outside of the body in the regions where PTV border was closer than 5 mm to, or outside of, 
the body surface. A new body-contour was defined that included this extra water structure. 
This was done to assure that the PTVs always had a distance of at least 5 mm to the body 
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surface for the optimization procedure. The final dose calculation was made on the original 
CT-scan, but also on the CT-scan with extra water structure in order to more correctly 
estimate the values of the dosimetric objectives reached for PTVT and PTVN. Sometimes 
additional optimization structures were delineated and used with objectives during the 
optimization of the H&N cases to achieve a more conformal dose distribution and reduce the 
dose between PTVN and PTVT. Those additional structures were located between PTVT and 
PTVN, and in some cases dorsally to the target.  
2.2.1 Balanced treatment plans 
In order to fulfill the treatment planning goals for the balanced plans in Eclipse, the objectives 
used in the optimization for those plans were slightly more stringent than the treatment goals 
shown in table 1 and 2. Upper and lower objectives were used to steer the maximum and 
minimum doses to target volumes. Upper objectives were also used in order to reduce the 
dose to the OARs and the additional structures defined and delineated as described in 2.2. To 
minimize the dose outside of the target, the normal tissue objective was used in the 
optimization. 
2.2.2 MCO treatment plans 
The objectives chosen for MCO differed somewhat in the two TPSs, depending on the 
choices available. In order to ensure target coverage in Eclipse, objectives for the target 
volumes were chosen. PRV spinal cord was also included in the MCO. An objective for dose 
homogeneity was included as well (which were only available in Eclipse MCO and not when 
creating the balanced plan). In RayStation, the minimum dose was selected for the target 
volumes, as well as an objective for the uniform dose to create uniformity of the dose within 
target. Dose fall off to the body was used in RayStation to achieve a more conformal dose 
distribution. This is similar to the normal tissue objective used when creating the balanced 
plan in Eclipse. Since no initial treatment plan was required in RayStation, the additional 
optimization structures were included in the RayStation MCO. To reduce the dose to the 
OARs, the maximum EUD with a = 1 were selected in both TPSs for the parallell built 
organs. In addition to objectives, constraints were also required for RayStation MCO. 
Constraints were selected in order to ensure target coverage and to minimize the dose to 
rectum and body for the prostate cases and the spinal cord and body for the H&N cases. The 
values for the constraints followed table 1 for the prostate cases and table 2 for the H&N 
cases, but were, in most cases, slightly more stringent. During trade-off navigation, the sliders 
for the targets were locked when they were close to their treatment goals and the sliders for 
the OARs were thereafter moved to reduce the dose as much as possible, but at the same time 
maintain the target coverage.  
 
Pareto plots were also made from the treatment plans in Eclipse and RayStation MCO by 
varying the dose to rectum and contralateral parotid for the prostate and the H&N cases 
respectively. Contralateral parotid represents the parotid on the low-dose side of the patient, 
i.e. close to the PTVN but further away from the PTVT. The value of rectum V90% and parotid 
contralateral Dmean were plotted against PTV D98% and PTVN D98% respectively.  
2.2.3 Post processing 
In RayStation, post processing was an option which was applied when the most desirable plan 
in MCO had been found. The optimization was then continued in the general plan 
optimization module. Objectives were added to reduce the dose to OAR volumes when the 
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dose of the plan in the MCO workspace was not satisfactory. This applied, for example, when 
OARs did not fulfill the treatment planning goals (and was not fully overlapping the target). 
For the prostate cases these volumes were mainly rectum and sometimes also the body. For 
the H&N cases these volumes were mainly the parotid glands and larynx, but sometimes also 
the body. Post processing was also used when desired to reduce hotspots in target.  
 
2.3 Evaluation of treatment plans 
Evaluation of the treatment plans were made during the optimization in order to decide if 
further optimization was needed. This was made by evaluating the dose distribution in the 
patient’s 3D volume for detection of any cold- or hotspots. Evaluation of the calculated DVH 
was also made by comparing the values of the dose/volume objectives specified in table 1 and 
2. When satisfied, the final values of the dose/volume objectives were compared for the 
different TPSs. The conformity index was thereafter calculated according to equation 1 [16] 
 
																																																																				𝐶𝑜𝑛𝑓𝑜𝑟𝑚𝑖𝑡𝑦	𝑖𝑛𝑑𝑒𝑥 = 	 &!,#$		
	&#$	
																								(1) 
where VT,pi is the volume of the target that is receiving the prescribed dose and Vpi is the total 
volume receiving the prescribed dose. The conformity index was calculated for PTV/PTVT 
with the 95%-isodose representing the prescribed dose. 
The heterogeneity index was calculated according to equation 2 [17] 
 
																																																𝐻𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑖𝑡𝑦	𝑖𝑛𝑑𝑒𝑥 = 	 (&%
((&%
                   (2) 
where D5% represents the dose in 5% of the target volume and D95% the dose in 95% of the 
target volume.  
Finally, the complexity of the treatment plans was also evaluated. The complexity was 
calculated according to the edge area metric (EAM) with an in-house developed MatLab 
software. The EAM depends on the amount of edge area for the MLC openings, where larger 
edge areas and smaller MLC openings are considered more complex. The EAM is based on 
equation 3 [15] 
																																																																												𝐸𝑑𝑔𝑒	𝑎𝑟𝑒𝑎 = 	 ))
))*	)*
                            (3) 
where R1 represents the region which encloses the area of 5 mm on both sides of the MLC 
boundaries and R2 represents the rest of the open area within the MLC opening.  
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3. Results  
3.1 Patients treated for prostate cancer 
Figure 2 shows an example of a dose distribution, for one selected patient treated for prostate 
cancer, together with isodose lines from a balanced treatment plan created in Eclipse. Figure 3 
illustrates the DVH for three treatment plans, also for one selected patient, one created in 
Eclipse MCO, one in RayStation MCO and one in RayStation MCO with post processing. 
 
 
Figure 2: Dose distribution of patient 1 in a balanced treatment plan created in Eclipse. The figure shows the sagittal 
CT image of the patient and the structures of PTV (blue) and rectum (green). However, the blue line for PTV does not 
show on the figure since it is covered by the yellow 95%-isodose. The goal is for the 95%-isodose to cover 98% of the 
volume of PTV. 
 
Figure 3: Example of a cumulative DVH for patient 1. The figure illustrates PTV, CTV and rectum for Eclipse MCO 
(solid line), RayStation MCO (dashed line) and RayStation MCO post processing (dotted line). 
The values for V90% and V50% for rectum of patient 1-5 are illustrated in figure 4 and 5 
respectively and the values of D98% for PTV are illustrated in figure 6. The scale on the y-axis 
in figure 4-6 is within the same range for easier comparision. The mean value and the range 
(minimum and maximum value) of the different dose/volume objectives evaluated for patient 
1-5 in Eclipse (balanced plan and MCO) and RayStation (MCO and MCO post processing) 




















Figure 4: Rectum V90% of patient 1-5 in Eclipse (balanced plan and MCO) and RayStation  
(MCO and MCO with post processing). Rectum V90% should aim to be less than 15% according to table 1. 
 
 
Figure 5: Rectum V50% of patient 1-5 in Eclipse (balanced plan and MCO) and RayStation  





Figure 6: PTV D98% of patient 1-5 in Eclipse (balanced plan and MCO) and RayStation  


























































Eclipse balanced plan Eclipse MCO RayStation MCO RayStation MCO post processing
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Table 3: Mean value and the range (minimum and maximum value) (%) for the dose/volume objectives for 
patient 1-5 for the treatment plans created in Eclipse (balanced plan and MCO) and RayStation (MCO and 




Balanced plan          MCO 
RayStation  
MCO                         MCO post processing 
CTV Dmin (%) 97.8 (97.4–98.3) 97.5 (97.3–97.6) 98.1 (97.2–98.4) 97.5 (97.1–98.2) 
PTV D98% (%) 96.4 (95.3–97.0) 95.5 (95.0–96.0) 96.2 (95.7–97.1) 95.5 (95.2–96.0) 
Rectum V90% (%) 12.8 (10.5–14.1) 11.6 (8.7–14.2) 13.2 (8.9–15.9) 11.5 (8.7–13.7) 
Rectum D2% (%) 98.8 (98.5–99.5) 99.5 (99.0–100.0) 99.6 (99.2–100.6) 99.0 (98.1–99.6) 
Rectum V50% (%) 30.7 (30.2–31.6) 27.6 (22.9–30.6) 32.3 (25.2–47.8) 27.6 (20.7–35.5) 
 
As illustrated in figure 4-6 and table 3, the values of the dose/volume objectives for PTV and 
CTV were quite similar in both TPSs, but there was a larger difference between the 
dose/volume objectives for rectum V50% and V90%. When MCO was applied in Eclipse, the 
results showed that it was possible to reduce the dose to rectum V50% and V90% but at the same 
time maintain target coverage. This in comparison with the balanced plan in Eclipse. Eclipse 
MCO provided, in most cases, a lower value for the dose/volume objectives than RayStation 
MCO and gave dosimetrically better treatment plans. However, after post processing, 
RayStation provided, in most cases, lower values to the OARs than Eclipse MCO.  
 
The MCO Pareto front is illustrated in figure 7 for rectum V90% and PTV D98% for the 
treatment plans of patient 1 created in Eclipse MCO and RayStation MCO. Each point in the 
figure illustrates a treatment plan where one of the dose/volume objectives cannot be 
improved without impairing the other treatment planning goal in the MCO navigation of the 
different TPSs. When the dose to rectum was reduced, the target coverage, i.e. the D98% for 
PTV, was also reduced.  
 
 
Figure 7: Pareto plot of PTV D98% and rectum V90% for patient 1 in Eclipse MCO and  




















Eclipse MCO RayStation MCO
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The evaluation of the plan quality was represented by conformity and heterogeneity index. 
The mean values of the conformity index for patient 1-5 were 0.89 and 0.9 for Eclipse 
(balanced plan and MCO) and 0.81 and 0.78 for RayStation (MCO and MCO post 
processing). The values for the heterogeneity index were similar for both TPSs. All values of 
these index for all patients can be seen in table 4 and 5. The calculated complexity index 
(EAM) were similar in both TPSs and followed the same pattern, which is illustrated in figure 
8. Figure 9 shows an exception with larger difference between the two TPSs. EAM is 
illustrated for arc 1 and 2 for Eclipse MCO and RayStation MCO post processing. All results 
for the individual patients can be seen in Appendix.  
  
Table 4: Conformity index for PTV for the treatment plans created for patient 1-5 in  





 Balanced plan            MCO 
RayStation 
            MCO                MCO post processing 
1 0.90 0.92 0.80 0.76 
2 0.86 0.89 0.76 0.72 
3 0.90 0.90 0.79 0.80 
4 0.89 0.90 0.87 0.85 




Table 5: Heterogeneity index for PTV for the treatment plans created for patient 1-5 in  





Balanced plan            MCO 
RayStation 
            MCO                MCO post processing 
1 1.04 1.04 1.04 1.05 
2 1.05 1.05 1.05 1.05 
3 1.04 1.04 1.06 1.06 
4 1.04 1.04 1.05 1.05 








Figure 8: EAM complexity index (y-axis) plotted for different gantry angles (x-axis) for the prostate cancer 





Figure 9: EAM complexity index (y-axis) plotted for different gantry angles (x-axis) for the prostate cancer 




3.2 Patients treated for H&N tonsil cancer  
Figure 10 shows an example of a dose distribution, for one selected patient treated for H&N 
cancer, together with isodose lines from a balanced treatment plan created in Eclipse. Figure 
11 illustrates the DVH for three treatment plans, also for one selected patient, one created in 




Figure 10: Dose distribution of patient 3 in a balanced treatment plan created in Eclipse. The figure shows the 
sagittal CT image of the patient and the structures of PTVT (light blue), PTVN (dark blue) and PRV spinal cord 
(green). For PTVT, the goal is for the 95%-isodose to cover 98% of the volume of PTVT. For PTVN, the goal is 





Figure 11: Example of a cumulative DVH for patient 4. The figure illustrates PTVT, PTVN, contralateral 
parotid, larynx and upper esophageal sphincter for Eclipse MCO (solid line), RayStation MCO (dashed line) 
and RayStation MCO post processing (dotted line). Contralateral parotid represents the value of parotid on the 
area with low dose area, i.e. PTVN. 
 
The values of Dmean for the contralateral parotid gland, larynx and upper esophageal spincter 
are shown in figure 12, 13 and 14 for patient 1-5. The value of D98% for PTVT and PTVN are 
illustrated in figure and 15 and 16. The scale on the y-axis in figure 12-16 is within the same 
range as in figures 4-6 for easier comparision. The mean value and the range (minimum and 
maximum value) of the different dose/volume objectives evaluated for patient 1-5 in Eclipse 
(balanced plan and MCO) and RayStation (MCO and MCO post processing) are shown in 
table 6. All results for the individual patients can be seen in Appendix.  
 
 
Figure 12: Dmean of the contralateral parotid gland for patient 1-5 in Eclipse (balanced plan and MCO) and 
RayStation (MCO and MCO with post processing). RayStation MCO with post processing was not applied for 
contralateral parotid for patient 3 and 5. Dmean should aim to be equal to, or less than 37% to each parotid 
gland. If only one gland could be spared, Dmean should aim to be equal to, or less than 29% for that gland. This 
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Figure 13: Dmean of larynx for patient 1-5 in Eclipse (balanced plan and MCO) and RayStation (MCO and 
 MCO with post processing). RayStation MCO with post processing was not applied for larynx for patient 1 and 5.  
Dmean should aim to be equal to, or less than 59% according to table 2.  
 
Figure 14: Dmean of upper esophageal sphintcer for patient 1-5 in Eclipse (balanced plan and MCO) and  
RayStation (MCO and MCO with post processing). Dmean should aim to be equal to, or less than 59% according 
 to table 2. RayStation MCO with post processing was only applied for upper esophageal sphintcher for patient 4.   
 
Figure 15: PTVT D98% for patient 1-5 in Eclipse (balanced plan and MCO) and RayStation  
(MCO and MCO with post processing). D98% should be more than, or equal to 95%  










































































Figure 16: PTVN D98% for patient 1-5 in Eclipse (balanced plan and MCO) and RayStation 
 (MCO and MCO with post processing). D98% should be more than, or equal to 74% according to table 2. 
 
Table 6: Mean value and the range (minimum and maximum value) (%) for the dose/volume objectives for 
patient 1-5 treated for cancer in the head and neck region for treatment plans created in Eclipse (balanced plan 




Balanced plan             MCO 
RayStation 
MCO                       MCO post processing      










PTVT* D98% (%) 95.5 (95.0–95.8) 96.5 (96.2–97.6) 96.7 (95.9–97.4) 95.9 (95.4–96.5) 
PTVN* D52.7% (%) 74.1 (73.6–74.9) 75.5 (75.0–75.9) 76.0 (74.8–77.2) 75.7 (74.4–77.3) 















Larynx Dmean (%) 57.6 (53.9–60.7) 53.0 (49.1–58.5) 53.8 (37.5–58.6) 50.9 (37.4–57.9) 
Oral cavity Dmean (%) 59.0 (40.0–72.1) 56.7 (34.5–70.0) 54.2 (35.7–72.1) 52.2 (33.8–71.3) 
Upper esophageal 









Mandible D2% (%) 99.4 (96.0–102.5) 100.1 (98.8–101.8) 99.8 (98.7–100.4) 100.0 (98.5–101.6) 















*The dose/volume objectives reported for PTVT and PTVN are from the CT-scans with extra water-
structure. 
 
The treatment plans calculated fulfilled the treatment planning goals in both TPSs for PTVT 
and PTVN (on the CT-scan with extra water-structure) and for PRV spinal cord, shown in 
table 6. The dose to the remaining OARs were optimized to be minimized based on their 
location relative to the tumor. As illustrated in figure 12-16, the values of the dose/volume 
objectives for PTVT and PTVN were quite similar in both TPSs, although there was a larger 
difference for the OARs. The largest differences were found for contralateral parotid, larynx 
and upper esophageal sphincter. When MCO was applied in Eclipse, the results showed that it 


















Eclipse balanced plan Eclipse MCO RayStation MCO RayStation MCO post processing
 
 17 
time maintain target coverage, as illustrated in figure 12-16. This in comparison with the 
balanced plan in Eclipse. However, after post processing, RayStation provided, in most cases, 
lower values to the OARs than Eclipse MCO. This is in agreement with the results for the 
prostate cases.   
The MCO Pareto front plot for Eclipse and RayStation MCO (CT-scan with extra water-
structure) for Dmean of the contralateral parotid gland and PTVN D98% for the treatment plans 
of the H&N patient 5 is illustrated in figure 17. When the dose to the parotid gland was 
reduced, the target coverage was also reduced in both treatment planning systems. However, 
the plot for Eclipse MCO were sharper, than the one for RayStation MCO, i.e for a certain 
reduction in target coverage, the dose reduction was larger for the parotid in Eclipse compared 
to the parotid in RayStation.  
 
 
Figure 17: Pareto plot of D98% for PTVN and Dmean for the contralateral parotid in Eclipse MCO and  
RayStation MCO. When the dose to parotid was reduced, D98% for PTVN was also reduced. 
 
 
The evaluation of the plan quality was represented by conformity index and heterogeneity 
index. The mean values for the conformity index were 0.88 and 0.87 for Eclipse (balanced 
plan and MCO) and 0.80 and 0.81 for RayStation (MCO and post processing). The values for 
the heterogeneity index were similar in both TPSs. All values of these index for all patients 
can be seen in table 7 and 8. However, the complexity index (EAM) differed between the two 
TPSs. This is illustrated in figure 18-19 where patient 1 is the one with largest difference and 
patient 3 is the one with least difference. EAM is illustrated for arc 1 and 2 for Eclipse MCO 
and RayStation MCO post processing. The treatment plans calculated in RayStation had 
generally a lower value of EAM than Eclipse. All results for the individual patients can be 
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Table 7: Conformity index for PTVT for the treatment plans created for patient 1-5 in  





 Balanced plan          MCO 
RayStation 
         MCO                MCO post processing 
1 0.90 0.90 0.82 0.83 
2 0.87 0.84 0.77 0.79 
3 0.91 0.88 0.82 0.82 
4 0.85 0.84 0.79 0.79 
5 0.87 0.86 0.82 0.83 
 
Table 8: Heterogeneity index for PTVT for the treatment plans created for patient 1-5 in  
Eclipse (balanced plan and MCO) and RayStation (MCO and MCO post processing). 
 
Patient 
                               Heterogeneity index 
Eclipse 
 Balanced plan            MCO 
RayStation 
            MCO                MCO post processing 
1 1.07 1.05 1.05 1.05 
2 1.07 1.05 1.05 1.06 
3 1.06 1.05 1.04 1.04 
4 1.06 1.04 1.04 1.05 





Figure 18: EAM complexity index (y-axis) plotted for different gantry angles (x-axis) for the H&N cancer patient 1 (arc 1 




Figure 19: EAM complexity index (y-axis) plotted for different gantry angles (x-axis) for the H&N cancer patient 3 (arc 1 





In this study, the multi-criteria optimization (MCO) in two different treatment planning 
systems have been evaluated for a total of ten patients which were represented by five patients 
treated for prostate cancer and five patients treated for H&N tonsil cancer. These diagnoses 
were selected considered that the OARs and target volumes differed. The prostate cases have 
a target with a regular shape and mainly one OAR in need to compromise with, meanwhile 
target for the H&N cases have an irregular shape and more OARs in need to compromise 
with, in comparison with the prostate cases. MCO has proven some advantages compared to 
conventional inverse treatment planning. For a beginner in treatment planning, in particular, it 
is quite intuitive. By changing one slider to fulfill one treatment planning goal, it was 
immediately shown what had to be compromised in order to achieve that goal. MCO 
facilitated the trade-offs between tumor coverage and normal tissue since the dose distribution 
and DVH was updated in real time. This will make it easier for other professional groups as 
oncologist to collaborate in the treatment planning. 
 
When the treatment plans were created, the aim was to give both TPSs as similar conditions 
as possible in order to compare the plans more fairly, but also since they were made by a 
beginner in both systems, it made the comparison more fairly. When using MCO in Eclipse, 
the results showed that it was possible to maintain target coverage, sometimes it was even 
improved, and at the same time reduce the dose to organs at risk compared to the balanced 
plans that were created with the conventional optimization algorithm. For example, Dmean to 
contralateral parotid for H&N patient 4 was reduced from 47.3% to 35.4% while the target 
coverage was still maintained. In RayStation MCO the corresponding value was 36.5%, 
which also was better than the balanced plan in Eclipse MCO. The results of the dose/volume 
objectives varied depending on the patient’s anatomy, but the overall result was that an 
improvement of the treatment plans was made with Eclipse MCO, compared to the 
conventional VMAT optimization in Eclipse, i.e. the balanced plan. When instead comparing 
RayStation MCO with the balanced plan in Eclipse, the results varied more, and an 
improvement of the treatment plans was not maintained in all cases. An example is for 
prostate cancer patient 3 where the dose to rectum V50% was reduced from 31.0% to 30.1% in 
Eclipse, but the corresponding value being 47.8 in RayStation MCO. This comparison also 
indicated differences between Eclipse MCO and RayStation MCO. All treatment plans for the 
prostate cases in Eclipse MCO provided lower values of the dose/volume objectives for 
rectum V50% and V90% than RayStation MCO (except for V50% for patient 4 which was 25.3% 
in Eclipse MCO and 25.2% in RayStation MCO, as shown in Appendix). This conclusion 
could not be drawn in the same way for the patients treated for H&N cancer as the results 
varied more for the different OARs. When instead comparing the time spent on the treatment 
plans in the different TPSs, VMAT treatment plans with MCO in RayStation required less 
time than Eclipse, since no initial treatment plan was required.  
 
The Pareto front plot for prostate patient 1 were quite similar for both TPS, i.e. comparable, 
although the values of rectum V90% were generally lower in Eclipse MCO than in RayStation 
MCO. This in agreement with the results when previously studying the dose/volume 
objectives where all treatment plans for the prostate cases in Eclipse MCO provided lower 
values of rectum V90% than RayStation MCO. However, there was a difference for the Pareto 
front plot of H&N patient 5, where the plot for Eclipse MCO were sharper than the one for 
RayStation MCO which indicated that for a certain reduction in target coverage, the reduction 
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for parotid was larger in Eclipse MCO than in RayStation MCO. Different TPS have different 
qualifications, so it is not an unexpected result. But the Pareto front plots were only made for 
two out of ten patients and only for two organs at risk. Pareto plots could further be used as a 
tool for evaluation which could have been done to a greater extent, i.e. for all patients and 
more dose/volume objectives evaluated in this study in order to find more variations. Previous 
studies have also evaluated the difference in Pareto plots depending on TPS. Petersson et al. 
[18] have been using Pareto fronts in different TPS as an evaluation tool. Intensity-modulated 
radiation therapy (IMRT) treatment plans were generated in SharePlan based on a plan from 
the TomoTherapy treatment system as input and in Oncentra MasterPlan for three prostate 
cases and three H&N cases. Those IMRT-plans were also compared to the treatment plans 
directly from the TomoTherapy system. When using Pareto front evaluation, the study 
showed that the plans generated in the different TPSs were comparable.  
 
Other studies have also evaluated the MCO algorithm. Miguel-Chumacero et al. [9] have 
shown that the trade-off between sparing of OARs and target coverage for H&N radiotherapy 
planning was improved by using MCO in Eclipse. They have concluded that the use of MCO 
enhanced plan quality. This is in agreement with the result from Eclipse in this study. 
Ghandour et al. [19] have evaluated MCO in RayStation with the conclusion that MCO 
provided reduction of treatment planning time without impairing dosimetric quality. This was 
not investigated in this study since no treatment plans without MCO were made in 
RayStation. 
 
The dose to the OARs in the treatment plans created in RayStation MCO could be reduced 
further with post processing by adding objectives and continue the optimization in the general 
plan optimization module. The post processing was an advantage when desired to reduce the 
dose to a specific volume (or volumes) which could not be done in the MCO module. It is an 
easy tool by just pushing that volume and lowering the dose, which in some cases even 
provided a lower dose to the OARs than Eclipse. However, the dose in the target was slightly 
lower when using RayStation MCO post processing to OARs in comparison with RayStation 
MCO. When the dose to an OAR is reduced, the whole dose distribution of the plan will be 
reduced which lead to impairment of the target coverage. Also, in the general plan 
optimization, the possibility of changing the sliders does not exist, nor the possibility of the 
understanding of what has to be compromised in order to fulfill a treatment planning goal. 
Working with post processing also required more time spent on the treatment plan than only 
working with MCO. However, post processing in RayStation required less time compared to 
creating the balanced plan prior to MCO in Eclipse.  
 
The lowest values for the dose/volume objectives for the OARs were in Eclipse provided by 
MCO and in RayStation they were provided by MCO with post processing. Furthermore, with 
post processing in RayStation the dose to the OARs was usually lower than Eclipse MCO.  
The heterogeneity index and conformity index were used for evaluation of the plan quality of 
the treatment plans. There are several definitions of heterogeneity and conformity index with 
different advantages and disadvantages. They can be valuable when evaluating plans and 
when choosing the best treatment plan among others. The results indicated that the treatment 
plans made in Eclipse were slightly more conform than the treatment plans made in 
RayStation but the heterogeneity was similar in all treatment plans. For the H&N cases, the 
value of EAM for the H&N cases indicated that treatment plans created in RayStation had a 
lower complexity than those created in Eclipse. This meant that the calculated dose 
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distribution of the treatment plans created in RayStation had a higher probability to differ less 
from the dose distribution that would be delivered to the patient for that treatment plan 
compared to the plans created in Eclipse. This shows the importance of evaluating the 
complexity and not only the calculated dose distribution. 
 
It is important to keep in mind that the treatment plans made in Eclipse and RayStation were 
created based on two different dose calculation algorithms (Eclipse AAA and RayStation 
CC). Different dose calculation algorithms affect the dose distribution, the optimization and 
partly the uncertainty in a complex plan in different ways. The impact of the different 
algorithms was not investigated in this study.  
 
The results in this study indicated that the patients treated for H&N cancer seemed to gain 
more of MCO in comparison to the patients treated for prostate cancer. This may be a result 
of a beginner creating the treatment plans. The treatment plans for the prostate cases were 
easier to accomplish than the H&N cases since the prostate cases do not have as many OARs 
that needs to be taken into account. This may have contributed to that the initial treatment 
plans in Eclipse for the prostate cases were closer to being true Pareto optimal plans than the 
ones for the H&N patients and fulfilled all treatment planning goals already before MCO. 
However, it would have been impossible to achieve all treatment planning goals for the H&N 
cases since many OARs were located so that they partially or fully overlapped the target 
volumes. This was the case for example the oral cavity, the parotids and the submandibular 
glands which applies regardless of the optimization method. In those cases, MCO was a tool 
that simplified the prioritizing between different OARs, which would have been more 
difficult to do in the conventional VMAT optimization and would have required more time 
spent on the treatment plan. However, one difficulty with MCO was knowing which 
objectives/constraints to select since this affected the creation of the Pareto surface. 
Depending on the objectives/constraints selected, it created an interval of the dose where the 
sliders could be moved. This in turn affected how much the dose to the OARs could be 
modified. Many options of different selections of objective/constraints were examined in both 
TPS and the one finally selected was the solution closest to the Pareto front. However, the 
sliders in Eclipse MCO and RayStation MCO could be moved to different minimum and 
maximum which affected the creation of the Pareto front surface. The interval for RayStation 
was narrower than the one for Eclipse. Though, this was not considered a problem when 
creating the treatment plans since the interval of the sliders were enough to be able to find a 
treatment plan for this study. However, it might have been possible to find even more 
satisfactory treatment plans if further Pareto plans were created in both treatment planning 







MCO has proven to be a useful tool for VMAT treatment planning which made it easier to 
understand what has to be compromised in order to achieve a treatment planning goal. When 
using MCO for VMAT treatment planning in Eclipse, the dose to OARs could be reduced 
while still maintaining the target coverage compared to the treatment plans created with 
conventional VMAT optimization in Eclipse. In RayStation, post processing was in many 
cases needed in order to make the treatment plans more desirable than what was achieved 
with only MCO. Dosimetrically, the treatment plans created in Eclipse MCO usually provided 
lower values to the OARs than the treatment plans created in RayStation MCO, but after post 
processing, RayStation were, in most cases, dosimetrically superior compared to Elipse MCO. 
The values for the heterogeneity index were similar in both Eclipse and RayStation, however, 
the conformity index was generally higher in Eclipse. The calculated complexity index was, 
in most cases, similar for the prostate cases, however the treatment plans for the H&N cases 
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8.1 Dose/volume objectives 
 
The results of the treatment planning for the dose/volume objectives evaluated in this study 
for all patients.  
 




              Eclipse 
Balanced plan     MCO 
RayStation 
        MCO          MCO post processing                   
CTV Dmin (%) 97.9 97.5 98.1 97.6 
PTV D98% (%) 96.9 95.3 97.1 95.2 
Rectum V90% (%) 12.6 9.9 13.0 9.5 
Rectum D2% (%) 98.7 99.2 99.2 99.4 
Rectum V50% (%) 30.2 22.9 25.5 20.7 
Body Dmax (%) 103.5 105.0 103.0 103.9 
 
 





Balanced plan        MCO                 
RayStation 
   MCO           MCO post processing                   
CTV Dmin (%) 97.8 97.6 98.4 97.1 
PTV D98% (%) 95.3 95.0 96.0 96.0 
Rectum V90% (%) 14.0 14.2 15.8 13.3 
Rectum D2% (%) 98.7 99.8 100.6 99.2 
Rectum V50% (%) 31.6 30.6 33.0 31.0 
Body Dmax (%) 103.4 103.9 103.5 104.7 
 
 





Balanced plan           MCO                                
RayStation 
        MCO         MCO post processing                   
CTV Dmin (%) 97.4 97.3 98.4 98.2 
PTV D98% (%) 96.2 95.2 96.5 95.2 
Rectum V90% (%) 14.1 13.0 15.9 13.7 
Rectum D2% (%) 98.7 99.0 99.3 99.6 
Rectum V50% (%) 31.0 30.1 47.8 35.5 
Body Dmax (%) 104.3 104.2 105.3 105.0 
 
 





Balanced plan           MCO                                
RayStation 
        MCO           MCO post processing                   
CTV Dmin (%) 98.3 97.6 98.3 97.2 
PTV D98% (%) 97.0 95.9 95.8 95.6 
Rectum V90% (%) 10.5 8.7 8.9 8.7 
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Rectum D2% (%) 98.5 100.0 99.8 98.1 
Rectum V50% (%) 30.4 25.3 25.2 22.0 
Body Dmax (%) 104.6 104.7 103.1 103.0 
 
 





Balanced plan          MCO                   
RayStation 
 MCO            MCO post processing                   
CTV Dmin (%) 97.6 97.3 97.2 97.4 
PTV D98% (%) 96.7 96.0 95.7 95.6 
Rectum V90% (%) 12.8 12.1 12.3 12.0 
Rectum D2% (%) 99.5 99.6 99.3 98.7 
Rectum V50% (%) 30.4 28.9 30.0 28.9 
Body Dmax (%) 104.3 104.4 103.3 103.8 
 
 
H&N cancer patient 1 
 
 
H&N cancer patient 2 
Dose/volume objective Eclipse 
Balanced plan          MCO                         
RayStation 
         MCO            MCO post processing      
PRV spinal cord D2% (%) 60.3 55.0 67.4 67.5 
PTVT D98% (%) 









PTVN D98% (%) 
























Larynx Dmean (%) 60.7 58.5 57.9 57.9 
Oral cavity Dmean (%) 72.1 70.0 72.1 71.3 
Upper esophageal sphincter Dmean (%) 57.2 53.0 54.7 54.6 
Mandible D2% (%) 102.5 101.4 99.4 99.4 















Body Dmax (%) 108.8 107.8 106.2 105.6 
Dose/volume objective Eclipse  
Balanced plan             MCO                          
RayStation 
       MCO             MCO post processing     
PRV spinal cord D2% (%) 58.1 53.7 58.8 60.1 
PTVT D98% (%) 









PTVN D98% (%) 




























H&N cancer patient 3 
 
 
H&N cancer patient 4 
Larynx Dmean (%) 56.2 49.1 58.6 52.6 
Oral cavity Dmean (%) 55.4 56.6 51.4 47.7 
Upper esophageal sphincter Dmean (%) 43.0 35.1 39.3 39.4 
Mandible D2% (%) 98.7 98.8 100.3 101.6 















Body Dmax (%) 109.9 107.3 107.9 108.5 
Dose/volume objective Eclipse 
Balanced plan          MCO                       
RayStation 
       MCO               MCO post processing      
PRV spinal cord D2% (%) 60.4 57.1 62.1 62.3 
PTVT D98% (%) 









PTVN D98% (%) 
























Larynx Dmean (%) 59.8 55.4 57.8 55.8 
Oral cavity Dmean (%) 40.0 34.5 35.7 33.8 
Upper esophageal sphincter Dmean (%) 57.8 51.7 34.8 34.8 
Mandible D2% (%) 98.7 99.2 98.7 98.5 















Body Dmax (%) 106.6 107.4 105.2 106.6 
Dose/volume objective Eclipse 
Balanced plan         MCO                         
RayStation  
MCO              MCO post processing      
PRV spinal cord D2% (%) 62.0 52.6 61.6 65.9 
PTVT D98% (%) 









PTVN D98% (%) 
























Larynx Dmean (%) 53.9 52.0 57.2 50.9 
Oral cavity Dmean (%) 67.6 62.7 57.7 54.3 
Upper esophageal sphincter Dmean (%) 54.9 54.0 54.7 51.0 
Mandible D2% (%) 101.3 101.8 100.4 100.8 


























The EAM plots for all patients and treatment plans illustrated for arc 1 and 2. 
 







Body Dmax (%) 107.9 106.5 106.4 106.7 
Dose/volume objective Eclipse 
Balanced plan           MCO                           
RayStation 
      MCO           MCO post processing      
PRV spinal cord D2% (%) 59.0 53.9 62.4 62.4 
PTVT D98% (%) 









PTVN D98% (%) 
























Larynx Dmean (%) 57.4 49.9 37.5 37.4 
Oral cavity Dmean (%) 60.0 59.7 54.0 53.8 
Upper esophageal sphincter Dmean (%) 56.7 48.7 27.6 27.5 
Mandible D2% (%) 96.0 99.1 100.3 99.5 















Body Dmax (%) 108.1 107.0 107.9 106.9 
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H&N cancer patient 5 
 
 
 
